Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00051545
Status:
TERMINATED
Last Update Posted:
2007-02-22
First Post:
2003-01-13
Brief Title:
Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma
Sponsor:
LEO Pharma
Organization:
LEO Pharma
Study Overview
Official Title:
Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma Efficacy of Seocalcitol EB 1089 Enteric-Coated Capsules 5 ug or Placebo in Prolonging Time to Relapse Following Intended Curative Resection or Percutaneous Ablative Treatment for Hepatocellular Carcinoma
Status:
TERMINATED
Status Verified Date:
2005-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy of Seocalcitol in prolonging time to relapse following intended curative resection or percutaneous ablative treatment ie percutaneous ethanol injections percutaneous acetic acid injections percutaneous microwave coagulation therapy or percutaneous radiofrequency ablation for hepatocellular carcinoma HCC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None